Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.64 |
| ▸ | DRD4 | P21917 | 12/20 | 0.64 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983538 | 0.92 | DRD2 (0.59) | DRD2DRD4DRD3ADRA1ASLC6A4 | |
| SCHEMBL8223555 | 0.91 | DRD3 (0.55) | DRD2DRD4DRD3ADRA1ASLC6A4 | |
| SCHEMBL8231965 | 0.88 | DRD4 (0.57) | DRD2DRD4DRD3SLC6A4SLC6A2 | |
| SCHEMBL3977153 | 0.88 | DRD3 (0.55) | DRD2DRD4DRD3ADRA1A | |
| SCHEMBL3977020 | 0.88 | DRD3 (0.61) | DRD2DRD4DRD3ADRA1A | |
| SCHEMBL3982334 | 0.87 | DRD2 (0.59) | DRD2DRD4DRD3ADRA1ASLC6A4 | |
| SCHEMBL13484970 | 0.87 | DRD3 (0.47) | DRD2DRD4DRD3ADRA1ASLC6A4 | |
| SCHEMBL3982327 | 0.85 | DRD3 (0.60) | DRD2DRD4DRD3ADRA1A | |
| SCHEMBL3976554 | 0.84 | DRD3 (0.58) | DRD2DRD4DRD3ADRA1A | |
| SCHEMBL3981916 | 0.84 | DRD3 (0.66) | DRD2DRD4DRD3ADRA1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | claimed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | DRD2 13/4885DRD4 26/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.